Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Psychiatry
Volume 2018, Article ID 9864285, 3 pages
https://doi.org/10.1155/2018/9864285
Case Report

Phenibut (β-Phenyl-γ-aminobutyric Acid) Dependence and Management of Withdrawal: Emerging Nootropics of Abuse

1Department of Pharmacy, New York University Langone Health, 550 First Avenue, New York, NY 10016, USA
2Department of Medicine, New York University Langone Health, 550 First Avenue, New York, NY 10016, USA
3New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
4Department of Psychiatry, New York University Langone Health, 550 First Avenue, New York, NY 10016, USA

Correspondence should be addressed to Tania Ahuja; gro.cmuyn@ajuha.ainat

Received 1 February 2018; Accepted 26 March 2018; Published 30 April 2018

Academic Editor: Lut Tamam

Copyright © 2018 Tania Ahuja et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

This case report describes the development of withdrawal from phenibut, a gamma-aminobutyric acid-receptor type B agonist. Although phenibut is not an FDA-approved medication, it is available through online retailers as a nootropic supplement. There are reports of dependence in patients that misuse phenibut. We report a case in which a patient experienced withdrawal symptoms from phenibut and was successfully treated with a baclofen taper. This case report highlights the development of phenibut use disorder with coingestion of alcohol and potential management for phenibut withdrawal. We believe clinicians must be aware of how phenibut dependence may present and how to manage the withdrawal syndrome.